Intermittent Claudication
Return to Library
|
Free Intermittent Claudication Articles |
|
|
|
|
Data from University of Connecticut advance knowledge in angiogenesis
2009 JUL 6 - (NewsRx.com) -- According to a study from the United States, "Gene transfer of FGF1 has been demonstrated to successfully promote angiogenesis. NV1FGF, a novel pCOR (conditional origin of replication) DNA plasmid-based gene delivery system, is in development by sanofi-aventis for the local expression of FGF1 in the treatment of peripheral vascular disease, and has demonstrated potential to induce therapeutic angiogenesis." "Preclinical studies using NV1FGF demonstrated restoration in capillary and arteriolar density in rabbit and hamster models of hind limb ischemia. In phase I and phase II clinical trials, NV1FGF effectively reduced the number of amputations and deaths in the trials, with minimal toxicity, and in conjunction with a sustained increase in mRNA and protein levels of FGF1 and its receptors in patients with critical limb ischemia (CLI). These results prompted a phase III trial of NV1FGF in patients with CLI, with the aim of improving quality of life," wrote N. Maulik and colleagues, University of Connecticut. The researchers concluded: "Thus, the results of the phase III clinical trial may be a significant advancement in the field of medical science, widening the reach of this therapeutic approach to effectively cure intermittent claudication and CLI." Maulik and colleagues published the results of their research in Current Opinion in Investigational Drugs (NV1FGF, a pCOR plasmid- based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia. Current Opinion in Investigational Drugs, 2009;10(3):259-268). For additional information, contact N. Maulik, University of Connecticut, Center Health, Dept. of Surgery Molecular Cardiology & Angiogenesis Laboratory, 263 Farmington Avenue, Farmington, CT 06030, USA. The publisher of the journal Current Opinion in Investigational Drugs can be contacted at: Thomson Reuters (Scientific) Ltd., 77 Hatton Garden, London, EC1N 8JS, England. Keywords: United States, Farmington, Angiogenesis, Angiology, Biotechnology, Clinical Trial Research, Clinical Trials, DNA, Drug Development, Gene Therapy, Genetics, Genomics, Intermittent Claudication, Ischemia, Oncology, Peripheral Artery Disease, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Pre-Trials Research, Sanofi-Aventis, Treatment, Tumor Vascularization, Vascular Disease, University of Connecticut. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
